Over $X,XXX,XXX raised so far.
Invest in Fisher
Wallace Laboratories
Wearable tech startup pursuing regulatory approval in the US and Europe for the treatment of depression, anxiety and insomnia.
Sign up with your email below to learn more and stay updated with Fisher Wallace.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Neuro-stimulation Technology For Treating Depression
85 million US adults experience symptoms of depression or anxiety, and 70 million suffer from sleep deprivation. These problems have similar scale in Europe. Drug therapy and behavioral therapy do not sufficiently or affordably address the growing mental health crisis.
.png)
Driven by Science & User Experience
The company's building its Version 2.0 device, OAK, while pursuing FDA approval and CE Marks (Europe/UK) for the treatment of depression, anxiety and insomnia.*
%20(1)%201.png)
Cutting Edge Research
Fisher Wallace recently completed a 255-subject, triple-blind, randomized, controlled trial for the acute treatment of major depressive disorder (pending publication), and is sponsoring an ongoing anxiety and insomnia study in collaboration with the Seattle Police Department.
Rapid Treatment Without Serious Side Effects
The company's recent depression study demonstrated rapid-action without serious side effects. Additional research conducted over the next 12 months in intended to obtain approval in the US and Europe.
Meet Our Team
.png)
Kelly Roman
Co-Founder, CEO, and Director
For more than a decade, Kelly Roman has helped pioneer the prescription wearable category and has expertise in product development, regulatory affairs, healthcare marketing and clinical trial strategy. Kelly has also served as an award-winning executive in the digital advertising and SaaS industries.
.png)
Charles "Chip" Fisher
Co-Founder, Chairman and Director
Charles “Chip” Fisher grew up in the electronics business - his father, Avery Fisher, founded Fisher Radio (later renamed Fisher Electronics). After serving as a sales executive at IBM, Chip acquired the original intellectual property to the Fisher Wallace Stimulator and is the company’s CFO and largest shareholder - and a recent TEDx contributor.
.png)
Simon Webster
Board Member
Simon is CEO of SHUFL Capital, the venture capital firm that recently invested in Fisher Wallace Laboratories. Earlier in his career, he led CPA Global on its 20 year journey from a £50m business to its recent public market entry at a value of £6.5bn.
.png)
Peter Rojas
Advisor
For more than a decade, Kelly Roman has helped pioneer the prescription wearable category and has expertise in product development, regulatory affairs, healthcare marketing and clinical trial strategy. Kelly has also served as an award-winning executive in the digital advertising
and SaaS industries.
Proven Product-Market Fit And Scalability
Leveraging a vertically integrated e-commerce model with an integrated telemedicine prescription process, Fisher Wallace has succeeded in generating over $40 million in lifetime revenue from its direct-to-patient sales channel.
"But since I couldn't stop talking about my good mood and hypercharged focus, my focus, my friends stopped laughing and started asking if the could borrow it. I'm reluctant to let go of my simulator, however."
"Columbia University Associate Clinical Professor of Psychiatry Richard P. Brown says he has used the device with 400 severely depressed patients and that more than 70% find relief, about twice the rate of anti-depressants."
Fisher Wallace is helping the Seattle Police Department to "normalize access to self care".
"The Fisher Wallace device...turned out to be the most impactful intervention in all my antidepressant exploration. At $499, it was an investment, but considering that most people with depression seek therapeutic treatments often not covered by health insurance, the possible savings on therapy and drugs over my lifetime seemed to justify the expense."
PERKS
Get rewarded for investing more into Fisher Wallace Laboratories.
$1,500
Tier 1
Invest $1,500+ and receive a free Fisher Wallace Version 2 Device and 2% bonus shares
%201.png)
$5,000
Tier 2
Invest $5,000+ and receive a free Fisher Wallace Version 2 Device and 5% bonus shares
$10,000
Tier 3
Free Fisher Wallace Version 2 Device and 10% bonus shares
%201.png)
$25,000
Tier 4
Invest $25,000+ and receive a free Fisher Wallace Version 2 Device, 15 % bonus shares
Invest in Fisher
Wallace Laboratories
Join us as we disrupt the mental health industry
Sign up with your email below to learn more and stay updated with Fisher Wallace.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
LEGAL DISCLAIMER
You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
©2023 Fisher Wallace Laboratories®
All Rights Reserved Privacy Policy |
Terms & Conditions
All Rights Reserved Privacy Policy |
Terms & Conditions